Share-based Payment Arrangement, Expense in USD of Cullinan Therapeutics, Inc. from 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cullinan Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2020 to Q3 2025.
  • Cullinan Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $9.47M, a 0.39% increase year-over-year.
  • Cullinan Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $38.4M, a 7.43% increase year-over-year.
  • Cullinan Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $37.8M, a 24.3% increase from 2023.
  • Cullinan Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $30.4M, a 8.87% increase from 2022.
  • Cullinan Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $28M, a 14.7% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cullinan Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $38.4M $9.47M +$37K +0.39% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 $38.3M $9.89M -$646K -6.13% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $39M $9.37M +$1.15M +13.9% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025
Q4 2024 $37.8M $9.63M +$2.12M +28.1% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025
Q3 2024 $35.7M $9.43M +$1.69M +21.8% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 $34M $10.5M +$2.61M +33% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 $31.4M $8.23M +$968K +13.3% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025
Q4 2023 $30.4M $7.52M +$6K +0.08% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025
Q3 2023 $30.4M $7.74M +$2.47M +46.8% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 $28M $7.92M -$688K -7.99% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 $28.7M $7.26M +$694K +10.6% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 $28M $7.51M -$4.63M -38.1% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024
Q3 2022 $32.6M $5.27M +$714K +15.7% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 $31.9M $8.61M +$4.44M +107% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 $27.4M $6.57M +$3.06M +87.1% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 $24.4M $12.1M 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023
Q3 2021 $4.56M 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 $4.17M 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022
Q1 2021 $3.51M 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022

Cullinan Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $37.8M +$7.39M +24.3% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025
2023 $30.4M +$2.48M +8.87% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025
2022 $28M +$3.58M +14.7% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024
2021 $24.4M +$9.47M +63.5% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023
2020 $14.9M 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.